Showing 5511-5520 of 9561 results for "".
- Melanoma Research Alliance Awards Inaugural Cohort of Nine Dermatology Research Fellowshttps://practicaldermatology.com/news/melanoma-research-alliance-awards-inaugural-cohort-of-nine-dermatology-research-fellows/2460139/In recognition of the critical role dermatologists can play in the prevention and early detection of melanoma, the Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, announced the inaugural cohort of nine dermatology research fellows. The fellows, whic
- DermTech Closes Combination with Constellation Alpha Capital Corphttps://practicaldermatology.com/news/dermtech-closes-combination-with-constellation-alpha-capital-corp/2460138/DermTech, Inc., a precision dermatology company enabled by a non-invasive skin genomics platform, has completed its previously announced business combination with Constellation Alpha Capital Corp., a publicly traded special purpose acquisition company prior to the business combination. As a resul
- FDA Approves Juvéderm Voluma XC For Mid-Face Injection Via Cannulahttps://practicaldermatology.com/news/fda-approves-juvederm-voluma-xc-for-mid-face-injection-via-cannula/2460137/Allergan’s Juvéderm Voluma XC is now U.S. Food and Drug Administration (FDA)-approved for cheek augmentation in the mid-face in adults over 21 with a TSK Steriglide cannula. This cannula features a patented tip design with a near-tip delivery port for precise product p
- ACS Study: Skin Creams Aren’t What We Thought They Werehttps://practicaldermatology.com/news/acs-study-skin-creams-arent-what-we-thought-they-were/2460136/Researchers report the first direct glimpse of how a skin cream or lotion is structured on the molecular scale, and it’s not quite what they expected. They presented their results at the American Chemical Society (ACS) Fall 2019 National Meeting & Exposition in San Diego.
- Amgen To Acquire Otezla® For $13.4 Billion In Cashhttps://practicaldermatology.com/news/amgen-to-acquire-otezla-for-134-billion-in-cash/2460135/Amgen has entered into an agreement with Celgene Corporation in connection with its previously announced merger with Bristol-Myers Squibb Company </
- Lilly’s Oral JAK Inhibitor Plus Steroids Improves AD Symptomshttps://practicaldermatology.com/news/lillys-oral-jak-inhibitor-plus-steroids-improves-ad-symptoms/2460134/Adding the oral JAK inhibitor baricitinib to standard-of-care topical corticosteroids significantly improved atopic dermatitis disease severity, measured by the validated Investigator's Global Assessment for AD (vIGA) score of "clear or almost clear" skin (vIGA 0, 1), the primary en
- Dr. Jennifer Soung Named New Psoriasis Editorhttps://practicaldermatology.com/news/dr-jennifer-soung-named-new-psoriasis-editor/2460129/Practical Dermatology magazine is pleased to announce that Jennifer Soung, MD is the new psoriasis editor. Dr. Soung, a dermatologist at Southern California Dermatology in Santa Ana, CA, will replace Jerry Bagel, MD. Her first feature article is slated to in the November 2
- PE in Dermatology: NavaDerm Partners with Laser & Skin Surgery Center of NYhttps://practicaldermatology.com/news/pe-in-dermatology-navaderm-partners-with-laser-skin-surgery-center-of-ny/2460119/NavaDerm is partnering with Laser & Skin Surgery Center of New York, Midtown Dermatology and their affiliated entities. Navaderm is a dermatology services organization in the Northeast and a BelHealth Investm
- Has Cellulite Finally Met its Match with BTL’s Emtone?https://practicaldermatology.com/news/has-cellulite-finally-met-its-match-with-btls-emtone/2460114/Drumroll please…BTL is launching Emtone, a device that targets cellulite via thermal monopolar radiofrequency and mechanical targeted pressure energy simultaneously. This combination results in increased production of collagen and elastin&
- Summer AAD News: Hyperhidrosis Updatehttps://practicaldermatology.com/news/summer-aad-news-hyperhidrosis-update/2460106/At least 15 million people in the U.S. experience diminished quality of life due to hyperhidrosis, yet half of people with the condition delay treatment for 10 years or more, according to information presented at the 2019 American Academy of Dermatology Summer Meeting in New York City.